TECON(SZ:002100) Xin Lang Zheng Quan·2025-09-19 03:30Core Viewpoint - TianKang Biological has shown a significant increase in stock price and trading volume, indicating positive market sentiment and potential growth in the agricultural and livestock sector [1][2]. Company Overview - TianKang Biological Co., Ltd. is located in Urumqi, Xinjiang, and was established on December 28, 2000, with its stock listed on December 26, 2006. The company specializes in the production and sales of biological vaccines for livestock, feed, and plant protein, as well as pig breeding, pig farming, slaughter processing, and meat product sales [1]. - The revenue composition of TianKang Biological includes: 32.20% from pig farming, 27.51% from feed, 16.37% from protein and oil processing, 14.75% from corn, 5.44% from veterinary drugs, and 3.40% from other sources [1]. Financial Performance - For the first half of 2025, TianKang Biological achieved an operating income of 8.847 billion yuan, representing a year-on-year growth of 10.68%. The net profit attributable to the parent company was 338 million yuan, reflecting a year-on-year increase of 22.27% [2]. - Since its A-share listing, TianKang Biological has distributed a total of 1.891 billion yuan in dividends, with 598 million yuan distributed over the past three years [3]. Shareholder Information - As of September 10, 2025, the number of shareholders of TianKang Biological was 69,400, an increase of 1.60% from the previous period. The average number of circulating shares per person decreased by 1.57% to 19,672 shares [2]. - Notable institutional shareholders include Guotai Zhongzheng Livestock Breeding ETF, which holds 15.5491 million shares, and Jiashi Agricultural Industry Stock A, holding 10.2945 million shares, both of which have increased their holdings compared to the previous period [3].